Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectrophotometry and differential scanning calorimetry
Van Hees, Thierry; Piel, Géraldine; Henry de Hassonville, Sandrineet al.
2002 • In European Journal of Pharmaceutical Sciences, 15 (4), p. 347-353
piroxicam; beta-cyclodextrin; UV spectrophotometry; inclusion complex; free/complexed drug ratio determination
Abstract :
[en] Few analytical techniques allow to evaluate the inclusion yield of cyclodextrin-drug complexes, because most manufacturing processes give amorphous products, In this study we have developed an alternative method to differential scanning calorimetry, to accurately determine the free/complexed piroxicam ratio by UV spectroscopy. This method is based on the differential solubility of the piroxicam-beta-cyclodextrin 1:2.5 mol/mol complex in water-acetonitrile (1:1 v/v) (Solvent A) or in anhydrous acetonitrile (Solvent B). both containing 0.05 M HCl. In anhydrous acetonitrile, beta-cyclodextrin is insoluble and the included drug remains entrapped, allowing the free piroxicam determination, while with 50% of water, the complex is totally dissolved, allowing the determination of the total guest content. This method was validated for linearity, precision and accuracy. The presence of cyclodextrin does not influence the assays, but more than 0.5% of water in Solvent B significantly affects the determination of the free piroxicam content. In comparison with differential scanning calorimetry, both delectability and precision were improved. It is now possible to analyse complexes with an inclusion purity greater than 99%. (C) 2002 Elsevier Science B.V. All rights reserved.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Van Hees, Thierry ; Université de Liège - ULiège > Département de pharmacie > Pharmacie clinique et pharmacie hospitalière
Piel, Géraldine ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique et magistrale
Henry de Hassonville, Sandrine
Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Delattre, Luc ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Language :
English
Title :
Determination of the free/included piroxicam ratio in cyclodextrin complexes: comparison between UV spectrophotometry and differential scanning calorimetry
Acerbi D., Bovis G., Carli F., Pasini M., Pavesi L., Peveri T. (1990) Biopharmaceutical optimisation of β-cyclodextrins inclusion compounds. Drug Invest. 2(SUPPL. 4):29-36.
Bertoluzza A., Rossi M., Taddei P., Redenti E., Zanol M., Ventura P. (1999) FT-Raman and FT-IR studies of 1:2.5 piroxicam-β-cyclodextrin inclusion compound. J. Mol. Struct. 480-481:535-539.
Braibanti A., Fisicaro E., Ghiozzi A., Compari C., Bovis G. (1998) Host-guest interactions between β-cyclodextrin and piroxicam. React. Funct. Polym. 36(3):251-255.
Caporal-Gautier J., Nivet J.M., Algranti P., Guilloteau M., Histe M., Lallier M., N'Guyen-Huu J.J., Russotto R. (1992) Guide de validation analytique: rapport d'une comission SFSTP. STP Pharma Prat. 2(4):205-226.
.
Dalmora M.E., Oliveira A.G. (1999) Inclusion complex of piroxicam with β-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int. J. Pharm. 184(2):157-164.
Deroubaix X., Stockis A., Allemon A.M., Lebacq E., Acerbi D., Ventura P. (1995) Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions. Eur. J. Clin. Pharmacol. 47(6):531-536.
1998, 19.
.
.
Fronza G., Mele A., Redenti E., Ventura P. (1992) Proton nuclear magnetic resonance spectroscopy studies of the inclusion complex of piroxicam with β-cyclodextrin. J. Pharm. Sci. 81(12):1162-1165.
Frömming K.H., Szejtli J., Cyclodextrins in Pharmacy, Dordrecht: Kluwer; 1994.
Gallagher R.T., Ball C.P., Gatehouse D.R., Gates P.J., Lobell M., Derrick P.J. (1997) Cyclodextrin-piroxicam inclusion complexes: analyses by mass spectrometry and molecular modelling. Int. J. Mass Spectrom. Ion Proc. 165-166:523-531.
Kurozumi M., Nambu N., Nagai T. (1975) Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with α- and β-cyclodextrins in powdered forms. Chem. Pharm. Bull. 23(12):3062-3068.
Lin S.Y., Kao Y.H. (1989) Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Int. J. Pharm. 56:249-259.
Piel G., Delneuville I., Delattre L. (1996) In vitro and in vivo studies on sodium nimesulide-β-cyclodextrin inclusion complex., Proc. 8th Int. Symp. Cyclodex; 487-490.
Redenti E., Peveri T., Zanol M., Ventura P., Gnappi G., Montenero A. (1996) A study on the differentiation between amorphous piroxicam-β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 129(1-2):289-294.
Redenti E., Zanol M., Ventura P., Fronza G., Comotti A., Taddei P., Bertoluzza A. (1999) Raman and solid state 13C-NMR investigation of the structure of the 1:1 amorphous piroxicam: β-cyclodextrin inclusion compound. Biospectroscopy 5(4):243-251.
Selva A., Redenti E., Zanol M., Ventura P., Casetta B. (1993) A study of β-cyclodextrin and its inclusion complexes with piroxicam and terfenadine by ionspray mass spectrometry. Org. Mass Spectrom. 28:983-986.
.
Van Hees T., Piel G., Evrard B., Otte X., Thunus L., Delattre L. (1999) Application of supercritical carbon dioxide for the preparation of a piroxicam-β-cyclodextrin inclusion compound. Pharm. Res. 16(12):1864-1870.
Woodcock B.G., Acerbi D., Merz P.G., Rietbrock S., Rietbrock N. (1993) Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur. J. Rheumatol. Inflam. 12(4):12-28.